SCHEMBL6313367

SCHEMBL6313367

Cc1nn(-c2ccccc2-c2ccccc2)cc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH1 Q13686 1/20 0.47
ALDH1A1 P00352 6/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TSHR P16473 1/20 0.42
HNF4A P41235 1/20 0.41
HTR2C P28335 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MYC P01106 2/20 0.41
NR4A1 P22736 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 2/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
POLB P06746 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765459 0.89 BCAT2 (0.49) ALKBH1ALDH1A1NPSR1HTR2CKDM4E
SCHEMBL1803916 0.81 NOTUM (0.52) ALKBH1ALDH1A1TSHRHTR2CMYC
SCHEMBL4298023 0.78 ALDH1A1 (0.59) ALKBH1ALDH1A1NPSR1L3MBTL1MAPT
SCHEMBL6763728 0.74 ALKBH1 (0.48) ALKBH1ALDH1A1TSHRHTR2CMYC
SCHEMBL13118030 0.74 LMNA (0.41) ALKBH1ALDH1A1MYCL3MBTL1MAPT
SCHEMBL14692523 0.73 NOTUM (0.56) ALKBH1TSHR
SCHEMBL22678498 0.72 LMNA (0.42) ALKBH1ALDH1A1L3MBTL1MAPTKDM4E
SCHEMBL6312258 0.72 ALKBH1 (0.44) ALKBH1ALDH1A1MYCL3MBTL1MAPT
SCHEMBL3835980 0.72 ALKBH2 (0.52) ALKBH1ALDH1A1NPSR1MYCL3MBTL1
SCHEMBL16578348 0.71 ALDH1A1 (0.41) ALDH1A1NPSR1HNF4ACYP2C9L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6974813-B2 N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia WARNER-LAMBERT COMPANY (US) 2005-12-13 US disclosed
US-20030149043-A1 N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia PFIZER INC. 2003-08-07 US disclosed
US-6492401-B1 SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE PFIZER, INC. 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149043-A1 N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia NHERF1, SLC28A1, TNNI3 ALKBH1 1179/4885ALDH1A1 642/4885NPSR1 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.